DDInter1840 DDInter259
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Trabectedin {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Trabectedin {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Docetaxel
Docetaxel {u} (Compound) resembles {v} (Compound) Cabazitaxel
Trabectedin {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Docetaxel
Docetaxel {u} (Compound) resembles {v} (Compound) Cabazitaxel
Trabectedin {u} (Compound) causes {v} (Side Effect) Peripheral sensory neuropathy
Peripheral sensory neuropathy {u} (Side Effect) is caused by {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Cabazitaxel
Trabectedin {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabazitaxel
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) regulates {v} (Gene) TUBB6
TUBB6 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound)
Trabectedin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Cabazitaxel (Compound)
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Trabectedin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Docetaxel (Compound) and Docetaxel (Compound) resembles Cabazitaxel (Compound)
Trabectedin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Docetaxel (Compound) and Docetaxel (Compound) resembles Cabazitaxel (Compound)
Trabectedin (Compound) causes Peripheral sensory neuropathy (Side Effect) and Peripheral sensory neuropathy (Side Effect) is caused by Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Cabazitaxel (Compound)
Trabectedin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) regulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Cabazitaxel (Compound)